.

CatalYm: First Patient Dosed NSCLC

Munich, Germany and San Francisco, USA, September 30, 2025 – CatalYm, today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company's anti-GDF-15 antibody visugromab, in combination with standard-of-care chemoimmunotherapy, compared to placebo plus chemoimmunotherapy, as a first-line treatment for patients with newly diagnosed metastatic non-squamous non-small cell lung cancer (NSQ mNSCLC).

CatalYm: Results Bladder Cancer

MUNICH & SAN FRANCISCO--(BUSINESS WIRE) September 23, 2025 – CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced two upcoming oral presentations highlighting the company's lead-candidate visugromab at the European Society of Medical Oncology (ESMO) Congress, being held October 17th - 21st, 2025, in Berlin, Germany.

CatalYm: Leadership Changes

Munich, Germany and San Francisco, USA, September 15, 2025 – CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as Chief Financial Officer and Chief Business Officer; Sujata Rao, MD, as Chief Medical Officer; Heike Krupka, PhD, as Chief Development Officer and Andrea Goddard as Chief Technology Officer represent a significant addition to the company's international development expertise.

Scenic Biotech: Dr. Bürli as CSO

Amsterdam, the Netherlands, September 09, 2025 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced the appointment of Roland W. Bürli, PhD, as Chief Scientific Officer (CSO), effective September 1, 2025. Dr. Bürli brings more than 25 years of experience in drug development and has held senior leadership roles across pharma and biotech companies.

Scenic Biotech publishes in Nature

Amsterdam, the Netherlands, September 03, 2025 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a publication in Nature on the role of ABHD18 as a missing link in the cardiolipin biosynthesis pathway. Cardiolipin is the signature phospholipid essential for mitochondrial function and implicated in both rare and common diseases. In a collaboration between Scenic and Dr. Jason Moffat's team at The Hospital for Sick Children (SickKids) in Toronto, the study aimed to identify modifier genes for Barth Syndrome (BTHS), an inborn error of cardiolipin metabolism, characterized by early onset cardiac and skeletal myopathy.

Scenic: License and Research Agreement

Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics.

Memo Therapeutics: Phase I Study

Schlieren / Zurich, Switzerland, 19 August, 2025 – Memo Therapeutics AG ("MTx") has published Phase I clinical data in Clinical and Translational Science, highlighting the safety, tolerability, and pharmacokinetics (PK) of its lead clinical asset, potravitug, a highly potent human monoclonal antibody targeting BK polyomavirus ("BKPyV").

Memo Therapeutics: Phase II Trial Results

Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus ("BKPyV")-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients ("KTR").

Memo Therapeutics on WTC 2025

Schlieren / Zurich, Switzerland, 19 June, 2025 – Memo Therapeutics AG (or "MTx") today announced that its late breaking abstract has been accepted for an oral presentation at the World Transplant Congress ("WTC") in San Francisco taking place 2-6 August 2025. The late breaking oral presentation will include interim results from the Phase II clinical trial evaluating potravitug.

Memo Therapeutics: Study Transcytosis

Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or "MTx") has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development.

.

xxnoxx_zaehler